patient-derived fibroblasts from skin biopsies cultured to 50% confluency after thawing an ampoule:
6 x 10e5 cells were transfected using an Amaxa 4D-Nucleofector (P2 Primary Cell Kit
from Lonza catalog# V4XP-2012, Program FF-135) with non integrating plasmids containing SOX2, KLF4,
L-MYC, LIN28, and a p53 shRNA vector (Addgene Cat.# 27077, 27078, 27080), according to Okita et al. with some modification. generated iPS cells were cultured feeder-free on matrigel coated plates. After characterization of the iPS cell lines cells were differentiated in Neural progenitor cells and further differentiated in a mixed population of glutamatergic and GABAergic neurons
BACKGROUND:
Individuals with 22q11.2 Deletion Syndrome (22q11.2 DS) are a specific high-risk group for developing schizophrenia (SZ), schizoaffective disorder (SAD) and autism spectrum disorders (ASD). Several genes in the deleted region have been implicated in the development of SZ, e.g., PRODH and DGCR8. However, the mechanistic connection between these genes and the neuropsychiatric phenotype remains unclear. To elucidate the molecular consequences of 22q11.2 deletion in early neural development, we carried out RNA-seq analysis to investigate gene expression in early differentiating human neurons derived from induced pluripotent stem cells (iPSCs) of 22q11.2 DS SZ and SAD patients.
METHODS:
Eight cases (ten iPSC-neuron samples in total including duplicate clones) and seven controls (nine in total including duplicate clones) were subjected to RNA sequencing. Using a systems level analysis, differentially expressed genes/gene-modules and pathway of interests were identified. Lastly, we related our findings from in vitro neuronal cultures to brain development by mapping differentially expressed genes to BrainSpan transcriptomes.
RESULTS:
We observed ~2-fold reduction in expression of almost all genes in the 22q11.2 region in SZ (37 genes reached p-value?0.05, 36 of which reached a false discovery rate?0.05). Outside of the deleted region, 745 genes showed significant differences in expression between SZ and control neurons (p?0.05). Function enrichment and network analysis of the differentially expressed genes uncovered converging evidence on abnormal expression in key functional pathways, such as apoptosis, cell cycle and survival, and MAPK signaling in the SZ and SAD samples. By leveraging transcriptome profiles of normal human brain tissues across human development into adulthood, we showed that the differentially expressed genes converge on a sub-network mediated by CDC45 and the cell cycle, which would be disrupted by the 22q11.2 deletion during embryonic brain development, and another sub-network modulated by PRODH, which could contribute to disruption of brain function during adolescence.
CONCLUSIONS:
This study has provided evidence for disruption of potential molecular events in SZ patient with 22q11.2 deletion and related our findings from in vitro neuronal cultures to functional perturbations that can occur during brain development in SZ.